The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The 1994 National Cancer Institute’s strategy to fund multi-institutional, multidisciplinary consortia to design and conduct early phase clinical trials in patients with high grade gliomas.
 
Stuart A. Grossman
Stock and Other Ownership Interests - Axxia Pharmaceuticals
Consulting or Advisory Role - Abbvie; Medicenna; Midatech Pharma
Patents, Royalties, Other Intellectual Property - Patent related to a subcutaneous polymeric opioid delivery system have been awarded.
 
Louis B. Nabors
Consulting or Advisory Role - BTG; Karyopharm Therapeutics
Patents, Royalties, Other Intellectual Property - Development of novel inhibitors to HuR through NCI funded peer reviewed research.
Other Relationship - University of Pennsylvania; ZIOPHARM Oncology
 
Joy D. Fisher
No Relationships to Disclose
 
Patrick Y. Wen
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; Blue Earth Diagnostics; Deciphera; deciphera; ElevateBio; Immunomic Therapeutics; Imvax; Integral Health; Karyopharm Therapeutics; KIYATEC; Puma Biotechnology; QED Therapeutics; Taiho Pharmaceutical; Taiho Pharmaceutical; Tocagen; Vascular Biogenics; VBI Vaccines; Voyager Therapeutics
Speakers' Bureau - Merck; Prime Oncology
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)
 
William C. Timmer
No Relationships to Disclose
 
Frederick G. Barker
No Relationships to Disclose
 
David M. Peereboom
Honoraria - Elsevier
Consulting or Advisory Role - Orbus Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Mylan (Inst); Neonc Technologies (Inst); Novartis (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); Stemline Therapeutics (Inst)
Travel, Accommodations, Expenses - Stemline Therapeutics
 
Benjamin M. Ellingson
Consulting or Advisory Role - Agios; Boston Biomedical; Global Coalition for Adaptive Research; Imaging Endpoints; Kazia Therapeutics; Medicenna; MedQIA; Neosoma; Northwest Biotherapeutics; Oncoceutics; Siemens; VBL Therapeutics
Research Funding - Janssen; Siemens
Travel, Accommodations, Expenses - Siemens
 
Jeffrey G. Supko
Employment - Ono Pharmaceutical (I)
Research Funding - Constellation Pharmaceuticals
 
Michelle A. Rudek
Employment - GlaxoSmithKline (I); Novavax (I)
Leadership - American Society for Clinical Pharmacology & Therapeutics
Stock and Other Ownership Interests - Novavax (I)
Research Funding - Celgene (Inst); Cullinan Oncology (Inst); RenovoRx (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Expert Medical Events
 
Ingo K. Mellinghoff
Honoraria - Roche
Consulting or Advisory Role - Agios; Black Diamond Therapeutics; Debiopharm Group; Puma Biotechnology; Voyager Therapeutics
Research Funding - Amgen; General Electric; Lilly
Travel, Accommodations, Expenses - Agios; AstraZeneca; Puma Biotechnology; Roche; Voyager Therapeutics
 
Tom Mikkelsen
Travel, Accommodations, Expenses - Roche/Genentech
 
Timothy Francis Cloughesy
Stock and Other Ownership Interests - Chimerix; Katmai Pharmaceuticals; Notable Labs
Consulting or Advisory Role - Abbvie; Agios; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; DelMar Pharmaceuticals; DNAtrix; Global Coalition for Adaptive Research; GW Pharmaceuticals; Inovio Pharmaceuticals; Karyopharm Therapeutics; Katmai Pharmaceuticals; KIYATEC; Merck; Novartis; Pascal Biosciences; Pfizer; QED Therapeutics; Roche/Genentech; Sapience Therapeutics; Tocagen; VBI Vaccines; VBL Therapeutics
Patents, Royalties, Other Intellectual Property - U.S. Provisional Application No.: 62/819,322 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Filing Date: March 15, 2019 Inventor(s): David A. Nathanson et al. FH Reference No.: UCH-17760 (32246-17760) Your Reference No.: [UCLA 2019-630-1] US
Other Relationship - Global Coalition for Adaptive Research
 
Michael Prados
Stock and Other Ownership Interests - Quadriga Biosciences; xCures
Consulting or Advisory Role - Nativis
Research Funding - Bristol-Myers Squibb (Inst); Day One Therapeutics (Inst); Genentech/Roche (Inst); Novartis (Inst); Oncoceutics (Inst); Regeneron (Inst)
Expert Testimony - Nativis; Oncoceutics
Travel, Accommodations, Expenses - Nativis; Oncoceutics
 
Glenn Jay Lesser
Honoraria - BTG; SDP Oncology
Consulting or Advisory Role - Agios; Cancer Expert Now; Incysus
Research Funding - Denovo Biopharma; Global Coalition for Adaptive Research; Incyte; Novocure; Oblato
Other Relationship - ASCO; NCI
 
E. Antonio Chiocca
Stock and Other Ownership Interests - DNAtrix; Immunomic Therapeutics; Seneca Therapeutics
Honoraria - GlaxoSmithKline; Merck
Consulting or Advisory Role - Advantagene; DNAtrix; InSightec; Merck; Sangamo Therapeutics; Voyager Therapeutics
Research Funding - Amgen; Newlink Genetics
Patents, Royalties, Other Intellectual Property - Patents related to oncolytic virus technology, gene therapy, microRNA, exosome, antibodies
 
Tracy Batchelor
Honoraria - Oakstone Publishing
Consulting or Advisory Role - GenomiCare
Patents, Royalties, Other Intellectual Property - American Cancer Society; Oxford University Press; UpToDate
 
Susan Marina Chang
Research Funding - Agios (Inst)
 
Frank S. Lieberman
Research Funding - Imvax (Inst); Inovio Pharmaceuticals (Inst); Novocure (Inst)
 
Xiaobu Ye
Patents, Royalties, Other Intellectual Property - Spouse receives royalty payment through Johns Hopkins University from Aspira Women's Health Inc. for licensed technologies. (I)